Utrecht, The Netherlands - SentryX, a clinical-stage biotechnology company developing implantable, sustained-release anesthetics for postoperative pain relief in spine surgery, today announced the installment of its Supervisory Board. This milestone reflects the company’s transition toward late-stage clinical development and its commitment to advancing innovative pain management solutions that reduce opioid use and improve surgical recovery outcomes.

The newly appointed Supervisory Board brings together leaders with deep expertise in medtech entrepreneurship, corporate finance, and long-term value creation. The board will play a strategic role in guiding SentryX as it prepares for its pivotal Phase 3 trial and future regulatory submissions.

Jan Sigger

Jan Sigger is a seasoned business executive and serial entrepreneur with extensive experience in the medical technology and pharmaceutical industry. He currently serves as Chairman of the Board at Solstice Pharmaceuticals and holds supervisory board positions at Sirius Medical and OCON. Previously, he was Co-Founder and CEO of Quirem Medical, where he led the company from inception through commercialization and eventual acquisition by Terumo Corporation. Prior to that, he played a pivotal role as Chief Operations & Financial Officer at Nucletron, contributing to its successful turnaround and sale to Elekta AB. With a strong track record in M&A, strategic execution, and innovation-driven growth, Jan brings deep industry insight and international leadership experience.

Nadine Maalouf

Nadine Maalouf is a seasoned executive with a long standing experience in Life Sciences and Healthcare. Before joining Van Lanschot Kempen in 2018, Nadine has held several M&A, BD, Sales and Marketing positions in pharma. Her core responsibility at Van Lanschot Kempen is to assist Life Sciences companies to fulfill their ambitions in M&A and Equity Capital Markets transactions. Nadine is committed to raise awareness about the high level of innovation within the European biotech space and favor deal-making through connecting emerging life sciences companies with key stakeholders of the investment community. Nadine is President of the Benelux Health Association and board member of the Nordic Pharma Licensing Group.

Koen de Heus

Koen de Heus is an investor and chairman of the family business Royal De Heus Group. Royal De Heus is an international company with a global top-10 position in the animal nutrition industry, with substantial positions in Europe, Asia and Afrika. Currently, De Heus has operating activities in more than 20 countries with a total revenue of 6 billion Euro and 12.000 employees. Additionally, Royal De Heus has considerable interests in companies in the value chain to support the animal nutrition activities and promote animal health.

“We are honored to welcome Jan, Nadine, and Koen to our Supervisory Board,” said Bas Oosterman, CEO and Co-Founder of SentryX. “Their combined experience across clinical innovation, investment strategy, and global business leadership will be instrumental as we work toward bringing our implantable anesthetic platform to patients worldwide. Their guidance will help us navigate the final clinical stages and prepare for market entry with a strong foundation.”

The formation of the Supervisory Board marks another important step in SentryX’s evolution from a pioneering startup to a late clinical-stage company, with a first-in-class solution that has already demonstrated significant reductions in pain and opioid use in early trials.